Adverse drug reactions with naltrexone: Experience from an addiction treatment center.  Sarkar S, Addagadda SS, Bhatia G, Chadda RK.  Indian J Psychiatry. 2021 Mar-Apr;63(2):206-207. doi: 10.4103/psychiatry.IndianJPsychiatry_94_20. Epub…

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.  Kosten T, Aharonovich E…

Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.  Perez-Macia V, Martinez-Cortes M, Mesones J, Segura-Trepichio M, Garcia-Fernandez L.  Patient Prefer Adherence. 2021 May 18;15:999-1015. doi: 10.2147…

Life threatening opioid withdrawal syndrome due to inadvertent naltrexone administration and lifesaving result by clonidine.  Kurmi J, Choudhury HA.  Indian J Psychiatry. 2020 Nov-Dec;62(6):742-743. doi: 10.4103/psychiatry.IndianJPsychia…

Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial Collins, Susan E et al. The Lancet Psychiatry, Volume 8, Issue 4, 2…

Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study).  Weimand BM, Solli KK, Reichelt WH, Tanum L. …